Close Menu

NEW YORK – Agios Pharmaceuticals said on Monday that its Phase III ClarIDHy trial did not demonstrate a statistically significant survival advantage for ivosidenib (Tibsovo) in patients with IDH1-mutated cholangiocarcinoma compared to placebo.

The ClarIDHy has already met its primary endpoint by demonstrating that patients with IDH1-mutated tumors on ivosidenib had a median progression-free survival of 2.7 months compared to 1.4 months on placebo. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct
29

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.